// App-Quantinova.ai

P613 : TLR9 SIGNALLING IS A POTENTIAL TUMOUR ESCAPE MECHANISM FOLLOWING BTKI THERAPY FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA.

Researchers

Presenter

  • Emma Kennedy

Principal Investigators

  • Simon Mitchell

  • Rosalynd Johnston

  • Iona Ashworth

  • Eleni Ladikou

  • Simon Mackay

  • Chris Pepper

Medical Centers

  • Brighton and Sussex University Hospitals NHS Trust,Brighton,Royaume-uni

  • Molecular and Clinical Cancer Medicine,Institute of Systems, Molecular and Integrative Biology, University of Liverpool,Liverpool,Vereinigtes Königreich

  • Cell Biology and Drug Discovery and Design Groups,Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde,Glasgow,Vereinigtes Königreich

  • Brighton and Sussex University Hospitals NHS Trust, Sussex Cancer Centre, Brighton, United Kingdom

  • Molecular and Clinical Cancer Medicine,Institute of Systems, Molecular and Integrative Biology, University of Liverpool,Liverpool,Vereinigtes Königreich

  • Department of Clinical and Experimental Medicine,Brighton and Sussex Medical School,Falmer,Vereinigtes Königreich

  • Department of Clinical and Experimental Medicine,Brighton and Sussex Medical School,Falmer,Vereinigtes Königreich

  • Molecular and Clinical Cancer Medicine,Institute of Systems, Molecular and Integrative Biology, Universit

  • Brighton and Sussex University Hospitals NHS Trust,Brighton,Vereinigtes Königreich

  • Brighton and Sussex University Hospitals NHS Trust, Sussex Cancer Centre, Brighton, United Kingdom

  • Cell Biology and Drug Discovery and Design Groups,Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde,Glasgow,Vereinigtes Königreich

  • Cell Biology and Drug Discovery and Design Groups,Strathclyde Institute of Phar

  • Department of Clinical and Experimental Medicine,Brighton and Sussex Medical School,Falmer,Vereinigtes Königreich

  • Department of Clinical and Experimental Medicine,Brighton and Sussex Medical School,Falmer,Vereinigtes Königreich

  • Brighton and Sussex University Hospitals NHS Trust, Sussex Cancer Centre, Brighton, United Kingdom

  • Brighton and Sussex Univer

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

  • CXCL12

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved